Evidence map›Paper›PMID 34099547›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2021

CDCP1 on Dendritic Cells Contributes to the Development of a Model of Kawasaki Disease.

Yu Lun, Nozha Borjini, Noriko N Miura, Naohito Ohno, Nora G Singer, Feng Lin

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. The biology of SCUBE.Journal of biomedical science · 2023
    Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Yu LunDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Nozha BorjiniDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Noriko N MiuraLaboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Hachioji, Tokyo, Japan; and.ORCID 0000-0002-4158-5100
Naohito OhnoLaboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Hachioji, Tokyo, Japan; and.
Nora G SingerDivision of Rheumatology, MetroHealth Medical Center, Cleveland, OH.ORCID 0000-0001-7041-723X
Feng LinDepartment of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA; linf2@ccf.org.
Cleveland Clinic Lerner College of Medicine · USTokyo University of Pharmacy and Life Sciences · JPMetroHealth · US

Funding

A novel regulator of Pseudomonas aeruginosa keratitisR01EY031463 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI LIN, FENG C, TAM, K. P. CONNIE · 2020 to 2023
$2.2M
Role of CD6 in the pathogenesis of autoimmune uveitisR01EY025373 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI LIN, FENG C · 2017 to 2021
$2.0M
A novel regulator of corneal wound healing and Pseudomonas aeruginosa keratitisR01EY030111 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI LIN, FENG C, TAM, K. P. CONNIE · 2019 to 2022
$1.6M
Complement and OsteoporosisR01AR061564 · NIAMS · CLEVELAND CLINIC LERNER COM-CWRU · PI DENNIS, JAMES E, LIN, FENG C · 2012 to 2015
$1.5M
Local inhibition of complement to improve MSC-based therapy for diabetesR01DK103581 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI HAMILTON, THOMAS A., LIN, FENG C · 2015 to 2018
$1.4M
Development of a novel antibody-drug conjugate for treating T-cell lymphoma.R41CA275639 · NCI · ABCON THERAPEUTICS, INC. · PI LIN, FENG C · 2022 to 2022
$403k
Cytokines and Complement in Nephritis and ColitisK01DK062945 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI LIN, FENG · 2003 to 2005
$363k
NCI NIH HHS R41 CA275639NEI NIH HHS R01 EY025373NEI NIH HHS R01 EY030111NEI NIH HHS R01 EY031463NIAMS NIH HHS R01 AR061564NIDDK NIH HHS K01 DK062945NIDDK NIH HHS R01 DK103581
6 · The paper itself

Abstract

The etiology and pathology of Kawasaki disease (KD) remain elusive. Cub domain-containing protein 1 (CDCP1), a cell-surface protein that confers poor prognosis of patients with certain solid tumors, was recently identified as one of the most significantly upregulated genes in SARS-CoV-2-infected children who developed systemic vasculitis, a hallmark of KD. However, a potential role of CDCP1 in KD has not previously been explored. In this study, we found that CDCP1 knockout (KO) mice exhibited attenuated coronary and aortic vasculitis and decreased serum

Indexed as

Disease Models, AnimalAnimalsAntigens, NeoplasmCell Adhesion MoleculesCells, CulturedDendritic CellsFemaleHumansMaleMiceMice, Inbred C57BLMice, KnockoutMucocutaneous Lymph Node SyndromeAntigens, NeoplasmCDCP1 protein, mouseCell Adhesion Molecules

Identifiers

PMID34099547
PMCPMC9011922
OpenAlexW3169366636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.